Compare XRTX & FEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XRTX | FEED |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | Canada | United States |
| Employees | 3 | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2018 | 2014 |
| Metric | XRTX | FEED |
|---|---|---|
| Price | $2.25 | $47.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 296.6K |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $318,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.29 |
| 52 Week High | $3.60 | $6.09 |
| Indicator | XRTX | FEED |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 96.25 |
| Support Level | $1.99 | $0.96 |
| Resistance Level | $2.29 | $6.09 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 33.33 | 89.76 |
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
ENvue Medical Inc is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. It focuses on two technology platforms: the ENvue Navigation Platform, which provides an electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract; FDA 510(k) cleared for adult use, it provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Its Medical advances non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation in healthcare environments, and the company's acoustic-based therapeutic technologies.